Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
VRTX Vertex Pharmaceuticals Incorporated
JOURNAVX is a non-opioid pain management therapy, aligning with the non-opioid pain management investable theme.
$108.47B
$416.41
-1.42%
VTRS Viatris Inc.
Pipeline includes non-opioid pain management options (e.g., fast-acting meloxicam) as growth drivers.
$12.08B
$10.29
+0.05%
AXSM Axsome Therapeutics, Inc.
Symbravo's non-opioid analgesic profile supports Non-Opioid Pain Management as a broader category.
$6.57B
$132.35
-0.87%
ATRC AtriCure, Inc.
Pain-management devices (cryoSPHERE family, cryoXT) provide non-opioid analgesia, a key product category.
$1.80B
$35.11
-3.68%
LXRX Lexicon Pharmaceuticals, Inc.
Pilavapadin is a non-opioid pain management therapy in development for neuropathic pain, constituting a non-opioid analgesic product category.
$497.55M
$1.31
-4.01%
ANIK Anika Therapeutics, Inc.
Non-opioid pain management solutions through HA injections address OA pain.
$139.69M
$9.77
+0.31%
SCLX Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
$126.38M
$18.67
+2.70%
ASRT Assertio Holdings, Inc.
INDOCIN, SPRIX, and CAMBIA represent non-opioid analgesics, supporting the Non-Opioid Pain Management theme.
$77.86M
$0.77
-4.67%
CPIX Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
$49.37M
$3.29
-0.45%
GRCE Grace Therapeutics, Inc.
GTx-101.00 is a non-narcotic topical analgesic in development for PHN, supporting the 'Non-Opioid Pain Management' theme.
$44.11M
$3.15
-1.25%
MIRA MIRA Pharmaceuticals, Inc.
The company's pain therapies are non-opioid analgesics, placing them under 'Non-Opioid Pain Management'.
$28.76M
$1.61
-5.00%
APUS Apimeds Pharmaceuticals US, Inc
Apitox functions as a non-opioid analgesic for pain management, aligning with the Non-Opioid Pain Management investable theme.
$23.57M
$2.02
-1.03%

Loading research report...

MIRA MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Ketamir‑2, Targets Chemotherapy‑Induced Neuropathic Pain

Oct 24, 2025
GRCE Grace Therapeutics, Inc.

Grace Therapeutics Raises $4.0 Million in Common Warrant Exercises Following FDA Acceptance of GTx‑104 NDA

Oct 23, 2025
CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Forms Joint Venture with RedHill Biopharma to Commercialize Talicia, a Leading H. pylori Therapy

Oct 20, 2025
MIRA MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals Announces Oral Mira‑55 Outperforms Injected Morphine in Pain and Inflammation Study, Supporting IND for Chronic Inflammatory Pain

Oct 16, 2025
CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Adds Vibativ to Premier Group Purchasing Agreement

Oct 13, 2025
SCLX Scilex Holding Company

Scilex Holding Company Completes First Tranche of Oramed Warrant Repurchase

Oct 01, 2025
SCLX Scilex Holding Company

Scilex Holding Company Closes Initial Tranche of $150 Million Investment in Datavault AI

Sep 26, 2025
SCLX Scilex Holding Company

Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI

Sep 25, 2025
SCLX Scilex Holding Company

Scilex Holding Company Explores Cryptocurrency Strategies with Biconomy.com

Sep 24, 2025
SCLX Scilex Holding Company

Semnur Pharmaceuticals Secures $100 Million Bitcoin Investment from Institutional Investor

Sep 23, 2025
SCLX Scilex Holding Company

Semnur Pharmaceuticals Completes Business Combination with Denali Capital, Becomes Public Company

Sep 22, 2025
SCLX Scilex Holding Company

Denali Capital Shareholders Approve Business Combination with Semnur Pharmaceuticals

Sep 04, 2025
SCLX Scilex Holding Company

Semnur Pharmaceuticals Secures $20 Million Private Placement for SP-102; Scilex CEO Jaisim Shah Transitions to Lead Semnur Full-Time

Aug 21, 2025
SCLX Scilex Holding Company

Semnur Pharmaceuticals' S-4 Registration Statement Declared Effective by SEC for Denali Business Combination

Aug 13, 2025
SCLX Scilex Holding Company

Scilex Holding Company Defers Semnur Preferred Stock Dividend Record Date Indefinitely

Jun 23, 2025
SCLX Scilex Holding Company

Scilex Holding Company Announces Peer-Review Publication on GLOPERBA® Dosing Adjustments

Jun 05, 2025
SCLX Scilex Holding Company

Scilex Holding Company Presents Positive SP-102 Post-Hoc Analysis for Lumbosacral Radicular Pain

May 16, 2025
SCLX Scilex Holding Company

Scilex Holding Company to Present SP-102 Post-Hoc Analysis at ASIPP Annual Meeting

May 01, 2025
SCLX Scilex Holding Company

Scilex Holding Company Regains Nasdaq Minimum Bid Price Compliance

Apr 30, 2025
SCLX Scilex Holding Company

Scilex Holding Company Changes Semnur Preferred Stock Dividend Record Date to May 2, 2025

Apr 22, 2025
SCLX Scilex Holding Company

Scilex Holding Company's Colchicine Granted FDA Orphan Drug Designation for Pericarditis

Apr 16, 2025
SCLX Scilex Holding Company

Scilex Holding Company Receives Health Canada Approval for ELYXYB® for Acute Migraine Treatment

Apr 15, 2025
SCLX Scilex Holding Company

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Apr 11, 2025
SCLX Scilex Holding Company

Scilex Holding Company Appeals Lower Court Decision in ZTlido Patent Infringement Lawsuit

Mar 26, 2025
SCLX Scilex Holding Company

Scilex Holding Company Changes Semnur Preferred Stock Dividend Record Date to April 11, 2025

Mar 10, 2025
SCLX Scilex Holding Company

U.S. Bankruptcy Court Extends Lock-up Period on Scilex Dividend Stock to April 14, 2025

Jan 31, 2025
SCLX Scilex Holding Company

Scilex Holding Company Files Q3 2024 10-Q and Regains Nasdaq Compliance

Jan 21, 2025
SCLX Scilex Holding Company

Scilex Holding Company Secures Worldwide Commercialization Rights for Gloperba®

Jan 16, 2025
SCLX Scilex Holding Company

Scilex Holding Company Changes Semnur Preferred Stock Dividend Record Date to January 28, 2025

Dec 30, 2024
SCLX Scilex Holding Company

Scilex Holding Company Closes $17 Million Registered Direct Offering

Dec 13, 2024
SCLX Scilex Holding Company

Scilex Holding Company Announces $17 Million Registered Direct Offering

Dec 12, 2024
SCLX Scilex Holding Company

Scilex Bio's KDS2010 Advances to Phase 2 for Obesity with Positive Phase 1 Results

Dec 11, 2024
SCLX Scilex Holding Company

Scilex Holding Company Appoints BPM LLP as New Independent Auditor

Dec 06, 2024
SCLX Scilex Holding Company

Scilex Holding Company Receives Nasdaq Non-Compliance Notice for Delayed Q3 2024 Filing

Nov 22, 2024
SCLX Scilex Holding Company

Semnur Pharmaceuticals Files S-4 Registration Statement for Proposed Business Combination with Denali Capital

Nov 06, 2024
SCLX Scilex Holding Company

Scilex Pharmaceuticals Achieves Agreed Path to NDA for SP-103 Following Successful FDA Phase II Meeting

Oct 30, 2024
SCLX Scilex Holding Company

Scilex Holding Company Addresses Allegations of Manipulative Short Selling

Oct 29, 2024
SCLX Scilex Holding Company

Scilex Holding Sets November 7, 2024, Record Date for Semnur Preferred Stock Dividend

Oct 28, 2024
SCLX Scilex Holding Company

Semnur Pharmaceuticals Anticipates SEC Filing for $2.5 Billion Business Combination

Oct 16, 2024
SCLX Scilex Holding Company

Scilex Holding Company Closes $50 Million Registered Convertible Financing

Oct 08, 2024
APUS Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. Welcomes FDA Draft Guidance for Non-Opioid Pain Therapies

Sep 12, 2025
APUS Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. Launches ai² Future Labs Program with University of Alabama Partnership

Aug 25, 2025
APUS Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. Reports Q2 2025 Financial Results and Identifies Material Weaknesses in Internal Controls

Aug 19, 2025
APUS Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. Appoints Dr. Susan Kramer as SVP of Development and Brian Peters as Head of ai² Division

Jul 15, 2025
APUS Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. Grants Shares and Options to CEO and CMO

May 16, 2025
APUS Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. Closes Initial Public Offering, Securing $11.90 Million in Net Proceeds

May 12, 2025
LXRX Lexicon Pharmaceuticals, Inc.

FDA Delays Feedback on Zynquista Data Submission for Type 1 Diabetes

Sep 22, 2025
LXRX Lexicon Pharmaceuticals, Inc.

Pilavapadin Demonstrates Meaningful Pain Reduction in DPNP at EASD and NEUROdiab Meetings

Sep 17, 2025
LXRX Lexicon Pharmaceuticals, Inc.

Lexicon Submits Additional Data to U.S. FDA Supporting Zynquista in Type 1 Diabetes

Sep 08, 2025
LXRX Lexicon Pharmaceuticals, Inc.

Lexicon Presents New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain

Sep 04, 2025

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks